Held by 5 specialist biotech funds
High Convergence# Signal Note: Avoro Capital Initiates $1.3B Position in UTHR Avoro's substantial new stake signals conviction in United Therapeutics' pulmonary hypertension (PH) franchise, likely driven by treprostinil's expansion potential across oral and inhaled formulations and the upcoming regulatory pathway for systemic sclerosis-associated PH (SSc-PAH), a high-unmet-need subset.
AI analyst context — unlock full analysis
**Signal Note: OrbiMed Initiates $51.3M Position in UTHR** OrbiMed's entry into UTHR likely reflects conviction in the company's pulmonary hypertension portfolio, particularly treprostinil's market expansion and potential label extensions, alongside the early-stage cell therapy programs (particularly cadaver donor heart regeneration). The $51.3M position size suggests meaningful conviction from a mega-fund operator with deep sector expertise, though timing of near-term catalysts (regulatory updates, Phase data) should be monitored for validation.
+ 3 more positions with dollar amounts and AI context
Unlock All — 7-Day Free Trial